Balance and movement improved in animal model of Parkinson ’s disease

This study is the first to demonstrate CLR01’s effectiveness in a mammal, one of the last important steps before human clinical trials.The researchers are now working on optimizing the blood-brain barrier penetration of CLR01 and measuring all the pharmacological features necessary for applying to the Food and Drug Administration to begin the first human, clinical trials.AUTHORSBitan and Dr. Marie-Fran çoise Chesselet, the Charles H. Markham professor of neurology at UCLA, are the senior authors of the study. Franziska Richter, assistant professor at the University of Leipzig in Germany, is the first author.JOURNALThepaper was published in the online edition of the journal Neurotherapeutics.FUNDINGThis work was supported by multiple funding agencies, including the National Institutes of Health, RJG Foundation, the Michael J. Fox Foundation, Team Parkinson/Parkinson Alliance, the American Parkinson ’s Disease Association, and gifts to the Center for the Study of Parkinson’s Disease at UCLA.
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news